Go back to doctor search

Amelia B. Zelnak, M.D., M.Sc.

Location Availability

Hospital Affiliation

  • Northside Hospital, Northside Hospital-Cherokee and Northside Hospital-Forsyth

Dr. Zelnak is a board-certified hematologist and medical oncologist with expertise in treating solid tumors, blood cancers and hematologic disorders. She completed training in internal medicine and was a fellow in hematology and oncology at the Emory University School of Medicine. Prior to joining Atlanta Cancer Care, Dr. Zelnak was part of the faculty at Emory University in the Department of Hematology and Medical Oncology.
Dr. Zelnak is part of the Northside Hospital Breast Care Committee, Northside Hospital Cancer Institute (NHCI) Breast Research Work Group, NHCI Research Advisory Committee, Susan G Komen Atlanta Advisory Council, and the Georgia NCORP Clinical Research Team.

Assisted By

Credentials

Board Certifications: Internal Medicine and Medical Oncology and Hematology.

Clinical Fellowship: Emory University School of Medicine

Internship and Residency: Emory University School of Medicine

Medical School: Emory University School of Medicine

Undergraduate: B.S., University of North Carolina at Chapel Hill

Hospital Affiliation: Northside Hospital, Northside Forsyth Hospital and Northside Cherokee Hospital

Education & Training

Fellowship

Emory University School of Medicine – Hematology/Oncology

Internship/Residency

Emory University School of Medicine – Internal Medicine

Medical School

Emory University School of Medicine

Research & Clinical Trials

Dr. Zelnak has been the Principle Investigator (PI) of numerous breast cancer clinical trials and she is committed to developing novel clinical trials for the management of early stage and metastatic breast cancer. She is the PI for the following clinical trials:

  • A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Paclitaxel in Combination With Reparixin Compared to Paclitaxel Alone as Front-line Therapy for Metastatic Triple- Negative Breast Cancer (FRIDA)
    www.clinicaltrials.gov/ct2/show/NCT02370238
  • Phase 2 Randomized, Double-Blinded, Controlled Study of ONT-380 vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
    www.clinicaltrials.gov/ct2/show/NCT02614794
  • An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments
    www.clinicaltrials.gov/ct2/show/NCT02574455
  • A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs.Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
    www.clinicaltrials.gov/ct2/show/NCT02445391

Northside Hospital researchers and Atlanta Cancer Care physicians work alongside respected industry partners and nationally recognized clinical trial networks to provide you with access to the latest treatments and prevention methods being tested through clinical trials.

Professional Memberships

  • American Society of Clinical Oncology
  • Georgia Society of Clinical Oncology

Publications

Dr. Zelnak has published several peer-reviewed research and review articles on breast cancer. Her most recent publications include:

  • Jegadeesh, N., Kim, S., Prabhu, R.S., Oprea, G., Yu, D., Godette, K.G., Zelnak, A., Mister, D., Switchenko, J., Torres, M.A. The 21-Gene Recurrence Score and Local Recurrence in Breast Cancer Patients. Ann Surg Oncol. 2015 Apr;22(4):1088-94.
  • Kandula, S., Switchenko, J.M., Fasola, C., Mister, D., Yu, D.S., Zelnak, A.B., Torres, M.A. Locoregional Recurrence Risk in Breast Cancer Patients with Estrogen Receptor Positive Tumors and Residual Nodal Disease following Neoadjuvant Chemotherapy and Mastectomy without Radiation Therapy. Int J Breast Cancer. 2015;2015:147476
  • Davis CC, Zelnak A, Eley JW, Goldstein DA, Switchenko JM, McKibbin T. Clinical Utility of Routine Cardiac Monitoring in Breast Cancer Patients Receiving Trastuzumab. Ann Pharmacother. 2016 Sep;50(9):712-7.
  • Zelnak, A.B., O’Regan, R.M. Optimizing Endocrine Therapy. J Natl Compr Canc Netw. 2015 Aug;13(8):e56-64

Clinical Interests

  • breast cancer and clinical trials

Honors & Awards

  • Morehead-Cain Scholar

Find a physician